[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100436311":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Children's Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ceftazidime avitbatan sodiumt group",null,"Children treated with ceftazidime avitbatan sodium in the pediatric intensive care unit will be enrolled in this group. Blood sample will be retained at various time intervals for pharmacokinetics.",[13],"Drug: Ceftazidime Avitbatan Sodium",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Ceftazidime Avitbatan Sodium","For 6-18 years children, 62.5 mg\u002Fkg\u002Fonce，q8h ; 3-6 months of age 50 mg\u002Fkg\u002F once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.",[9],[21],{"name":22,"affiliation":5,"role":23},"Guoping Lu, doctor","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Yixue Wang, Doctor","CONTACT","8613524669352","yixuewang08@aliyun.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Children's hosptial of fudan university","RECRUITING","Shanghai","Shanghai Municipality","201102","China","CN",{"type":40,"coordinates":41},"Point",[42,43],121.45806,31.22222,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":10,"email":49},"LU guoping, dotor","18017590817","13788904150@163.com",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100436311","pkpd-of-ceftazidime-avitbatan-sodium-in-children-with-severe-infection-100436311",false,"NCT04961580","PK\u002FPD of Ceftazidime Avitbatan Sodium in Children With Severe Infection","Pharmacokinetics and Pharmacodynamics of Ceftazidime Avitbatan Sodium in Children With Severe Infection","Inclusion Criteria:\n\n* Children who are admitted in the pediatric intensive care unit receiving ceftazidime avitbatan sodium\n\nExclusion Criteria:\n\n* No Informed Consent signed\n* Participate in other clinical trials","ALL","3 Months","18 Years",{"count":63,"type":64},30,"ESTIMATED","OBSERVATIONAL","Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe infections is not unusual. Pathophysiological changes in severe sepsis can lead to significant changes in pharmacokinetics and pharmacodynamics during continuous renal replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic in severe infection children with extracorporeal life support, thus improve the treatment of severe sepsis and sepsis shock.",[68,69],"Sepsis","Antibiotic Reaction","2026-03-13",{"date":72,"type":73},"2026-03-16","ACTUAL",{"date":75,"type":73},"2022-10-01",{"date":77,"type":64},"2026-12-31",{"name":5,"class":6},1]